A Study of LY3473329 in Healthy Participants

A Safety, Tolerability, and Pharmacokinetic Study of Single-and Multiple-Ascending Doses of LY3473329 in Healthy Subjects

The main purpose of this study in healthy participants is to learn more about the safety of LY3473329 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3473329 gets into the bloodstream and how long the body takes to eliminate it. This is a two-part study. Participants may only enroll in one part.

For each participant:

• Part A will last up to about 19 weeks and may include 9 visits.
• Part B will last up to about 28 weeks and may include 11 visits.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Placebo; Drug: LY3473329

• Study Type: Interventional
• Enrollment (Actual): 86
• Phase: Phase 1

Contacts and Locations

Study Locations

• Netherlands
  • Groningen, Netherlands, 9728
    • PRA Health Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 54 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males and females must adhere to contraception restrictions
• Have clinical laboratory test results within normal reference range or with acceptable deviations
• Body mass index (BMI) less than or equal to (≤)30 kilograms per square meter (kg/m²)

• For Part B:

  • Lipoprotein (a) (Lp[a]) greater than or equal to (≥)75 nanomoles per Liter (nmol/L) or 30 milligrams per deciliter (mg/dL) at screening
  • Plasminogen is within the normal range at screening

Exclusion Criteria:

• Are currently enrolled in, or discontinued within the past 30 days from, a clinical trial involving an investigational drug that has not received regulatory approval for any indication, except for any trial involving antisense Lp(a), for which 6 months must have passed from the participant's last study drug dose
• Have previously completed or withdrawn from this study or any other study investigating LY3473329
• Are pregnant or breast feeding
• Glomerular filtration rate (GFR) is lower than estimated GFR 60 milliliters per minute per 1.73 square meters (mL/min/1.73 m2) using the Modification of Diet in Renal Disease Study equation
• Have a history or presence of medical illness including, but not limited to, any cardiovascular, thromboembolism or bleeding disorder, hepatic, respiratory, hematological, endocrine, immune, psychiatric or neurological disease, convulsions, or any clinically significant laboratory abnormality that, in the judgment of the investigator, indicate a medical problem that would preclude study participation
• Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study. In addition, participants with the following findings will be excluded: Confirmed Fridericia's corrected QT interval greater than (>)450 milliseconds (msec) for men and >470 msec for women. One additional ECG may be performed if required
• Have an elevated high-sensitivity C-reactive protein (>3 milligrams per Liter [mg/L]) or have a prothrombin time/international normalized ratio (PT/INR) or activated partial thromboplastin time (aPTT) >1.25 times (x) upper limit of normal (ULN)
• Are an investigator or site personnel directly affiliated or immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted
• Are Lilly employees or contractors or an immediate family member of such
• Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies, hepatitis C and/or positive hepatitis C antibody, or hepatitis B and/or positive hepatitis B surface antigen
• Have donated more than 500 milliliters (mL) of blood within the past month
• Are unwilling to stop alcohol consumption while resident in the clinical research unit (CRU)
• Have an average weekly alcohol intake that exceeds 21 units per week (1 unit = 12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
• Have an abnormal blood pressure (supine) defined as diastolic blood pressure >95 or less than (<)45 millimeters of Mercury (mmHg) and/or systolic blood pressure >160 or <90 mmHg. Re-testing may occur once during screening within 2 hours of the initial abnormal blood pressure measurement at the discretion of the investigator at screening
• Have positive findings for known drugs of abuse on urinary drug screening
• Positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus nasopharyngeal polymerase chain reaction (PCR) test at Day -1
• Contact with SARS-CoV-2- positive or corona virus disease 2019 (COVID-19) patient within the last 14 days prior to admission to the clinical unit
• In the opinion of the investigator or the sponsor, are unsuitable for inclusion in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo (Part A); Placebo administered orally.	Drug: Placebo; Administered orally.
Experimental: LY3473329 (Part A); LY3473329 administered orally.	Drug: LY3473329; Administered orally.
Experimental: LY3473329 (Part B); LY3473329 administered orally.	Drug: LY3473329; Administered orally.
Experimental: Placebo (Part B); Placebo administered orally.	Drug: Placebo; Administered orally.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module	Baseline up to Day 137

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3473329	PK: AUC of LY3473329	Baseline up to Day 137
PK: Maximum Observed Drug Concentration (Cmax) of LY3473329	PK: Cmax of LY3473329	Baseline up to Day 137

Collaborators and Investigators

• Sponsor: Eli Lilly and Company

Study record dates

Study Major Dates

• Study Start (Actual): August 18, 2020
• Primary Completion (Actual): November 9, 2021
• Study Completion (Actual): November 9, 2021

Study Registration Dates

• First Submitted: July 14, 2020
• First Submitted That Met QC Criteria: July 14, 2020
• First Posted (Actual): July 15, 2020

Study Record Updates

• Last Update Posted (Actual): December 14, 2021
• Last Update Submitted That Met QC Criteria: December 13, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: 17611; J2O-MC-EKBA (Other Identifier: Eli Lilly and Company); 2020-002522-91 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No